Back

HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic advances in amyloid cardiomyopathy Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

5 More presentations in this session

Presentation thumbnail
Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
Doctor M. Grogan (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101
Doctor F. Aus Dem Siepen (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy
Doctor B. Forst (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
RNA interference therapy in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
Mr G. Arrighini (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
The UNOS experience on heart transplantation for amyloid cardiomyopathy
Associate Professor A. Briasoulis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Therapeutic advances in amyloid cardiomyopathy
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis
thumbnail
Congress Session
Advances in amyloidosis
thumbnail
Congress Presentation
Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources